γ-secretases: from cell biology to therapeutic strategies
- 1 February 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 9 (2), 215-226
- https://doi.org/10.1016/s1474-4422(09)70332-1
Abstract
No abstract availableThis publication has 126 references indexed in Scilit:
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Presenilins are essential for regulating neurotransmitter releaseNature, 2009
- NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- Neuronal calcium mishandling and the pathogenesis of Alzheimer's diseaseTrends in Neurosciences, 2008
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Substrate-targeting γ-secretase modulatorsNature, 2008
- Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel GatingNeuron, 2008
- Presenilins Form ER Ca2+ Leak Channels, a Function Disrupted by Familial Alzheimer's Disease-Linked MutationsCell, 2006